SSTI is focused on the discovery and development of novel small-molecule drugs that target developmental pathways fundamental to cancer. Our mission is to optimize efficacy against developmental pathways that drive cancer, such as the WNT, Sonic Hedgehog (SHH) and Notch signaling pathways. The goal of our programs is to develop novel therapeutics to effectively treat cancer by blocking the cancer stem cells.
With its next generation of cancer therapeutics, SSTI has the potential to impact the lives of millions of cancer patients worldwide. Approximately 1.5 million Americans will be diagnosed with cancer this year, and over half a million will die of their disease. Although death rates for a large number of human diseases have declined over the last fifty years, many patients with cancer continue to have dismal five-year survival. This point illustrates the largely unmet need for better cancer treatments that prevent recurrence and metastatic disease.
SSTI is currently focusing on breakthrough technologies in the WNT, SHH and Notch signaling arenas. SSTI has already identified potent inhibitors of WNT and SHH signaling, and has IP protection on multiple lead compounds. With a multi-pronged scientific approach our scientists are generating many agents targeting critical cancer stem cell pathways.
- Through SSTI chemistry, a series of potent WNT and SHH inhibitors have been developed that reduce tumor burden in vivo.
- SSTI has filed a composition of matter patent, which has been published for these compounds. SSTI is the exclusive owner of this intellectual property.
- We have identified a novel mechanism of action, and cellular target.
- These compounds represent first-in class agents for the WNT pathway in cancer.